UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Polarization Dependence of Optical Properties of Single-Mode Polymer Optical Waveguides Fabricated Under Different Processes at 1310/1550 nm

Journal of lightwave technology, 2020-07, Vol.38 (14), p.3670-3676

2020

Volltextzugriff (PDF)

Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review

Journal of clinical medicine, 2020-05, Vol.9 (5), p.1362

2020

Volltextzugriff (PDF)

Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer

Cancer letters, 2021-12, Vol.522, p.119-128

2021

Volltextzugriff (PDF)

Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab

Internal Medicine, 2021/11/15, Vol.60(22), pp.3585-3588

2021

Volltextzugriff (PDF)

Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study

Oncoimmunology, 2021-01, Vol.10 (1), p.1950411-1950411

2021

Volltextzugriff (PDF)

Durable Response to Chemoimmunotherapy of a Lung Adenocarcinoma Harboring a MET Exon 14 Skipping Mutation

Curēus (Palo Alto, CA), 2023-02

2023

Volltextzugriff (PDF)

Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study

Frontiers in oncology, 2021-03, Vol.11, p.630136-630136

2021

Volltextzugriff (PDF)

Safety of First-Line Nivolumab Plus Ipilimumab in Very Old (≥ 80 Years) Patients With Unresectable Malignant Pleural Mesothelioma: A Retrospective Single-Center Case Series

Curēus (Palo Alto, CA), 2024-01

2024

Volltextzugriff (PDF)

HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features

NPJ precision oncology, 2022-01, Vol.6 (1), p.5-5, Article 5

2022

Volltextzugriff (PDF)

Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients

Medical oncology (Northwood, London, England), 2020-12, Vol.37 (12), p.111-111, Article 111

2020

Volltextzugriff (PDF)

Impact of docetaxel plus ramucirumab in a second‐line setting after chemoimmunotherapy in patients with non‐small‐cell lung cancer: A retrospective study

Thoracic cancer, 2022-01, Vol.13 (2), p.173-181

2022

Volltextzugriff (PDF)

The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study

Frontiers in oncology, 2021-05, Vol.11, p.663612-663612

2021

Volltextzugriff (PDF)

Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR‐T790M mutation in non‐small cell lung cancer cells

Cancer medicine (Malden, MA), 2022-02, Vol.11 (4), p.944-955

2022

Volltextzugriff (PDF)

Design for polymer optical waveguides realizing efficient light coupling via 45-degree mirrors

Optics express, 2019-04, Vol.27 (8), p.10839-10853

2019

Volltextzugriff (PDF)

Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study

Translational lung cancer research, 2021-08, Vol.10 (8), p.3582-3593

2021

Volltextzugriff (PDF)

Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study

JTO clinical and research reports, 2022-07, Vol.3 (7), p.100353-100353, Article 100353

2022

Volltextzugriff (PDF)

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC

JTO clinical and research reports, 2022-09, Vol.3 (9), p.100388-100388, Article 100388

2022

Volltextzugriff (PDF)

Low-loss light coupling with graded-index core polymer optical waveguides via 45-degree mirrors

Optics express, 2016-02, Vol.24 (4), p.3550-3561

2016

Volltextzugriff (PDF)

Concurrent hemoptysis and pulmonary embolism associated with lenvatinib therapy for unresectable thymic carcinoma: A case report

Current problems in cancer. Case reports, 2022-06, Vol.6, p.100164, Article 100164

2022

Volltextzugriff (PDF)

Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial

JTO clinical and research reports, 2022-12, Vol.3 (12), p.100424, Article 100424

2022

Volltextzugriff (PDF)

Interferon-β signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells

Biochemical and biophysical research communications, 2018-12, Vol.507 (1-4), p.330-336

2018

Volltextzugriff (PDF)

Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2021-11, Vol.161, p.26-33

2021

Volltextzugriff (PDF)

Association of immune checkpoint inhibitors with respiratory infections: A review

Cancer treatment reviews, 2020-11, Vol.90, p.102109, Article 102109

2020

Volltextzugriff (PDF)

Can the assessment of lymphocyte exhaustion serve as a prognostic predictor after lung cancer surgery?

Translational lung cancer research, 2020-04, Vol.9 (2), p.184-187

2020

Volltextzugriff (PDF)

1 – 25 von 153

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(112)
Mit Volltextzugriff
(132)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Polarization Dependence of Optical Properties of Single-Mode Polymer Optical Waveguides Fabricated Under Different Processes at 1310/1550 nm

Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review

Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer

Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab

Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study

Durable Response to Chemoimmunotherapy of a Lung Adenocarcinoma Harboring a MET Exon 14 Skipping Mutation

Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study

Safety of First-Line Nivolumab Plus Ipilimumab in Very Old (≥ 80 Years) Patients With Unresectable Malignant Pleural Mesothelioma: A Retrospective Single-Center Case Series

HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features

Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients

Impact of docetaxel plus ramucirumab in a second‐line setting after chemoimmunotherapy in patients with non‐small‐cell lung cancer: A retrospective study

The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study

Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR‐T790M mutation in non‐small cell lung cancer cells

Design for polymer optical waveguides realizing efficient light coupling via 45-degree mirrors

Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study

Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC

Low-loss light coupling with graded-index core polymer optical waveguides via 45-degree mirrors

Concurrent hemoptysis and pulmonary embolism associated with lenvatinib therapy for unresectable thymic carcinoma: A case report

Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial

Interferon-β signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells

Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer

Association of immune checkpoint inhibitors with respiratory infections: A review

Can the assessment of lymphocyte exhaustion serve as a prognostic predictor after lung cancer surgery?

Suchergebnisse filtern